Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy A rare case report

Rationale: Primary pleural angiosarcoma (PPA) is an extremely rare malignancy for which there is no consensus on treatment. The clinical course of PPA is usually quickly fatal, regardless of the treatment used. Patient concerns: We describe the rare case of a 52-year-old man who presented initially with hemoptysis and received emergency surgery for the primary. Diagnoses: He received a confirmed diagnosis of primary pleural angiosarcoma (PPA) by postoperative pathology and was subsequently treated with radiotherapy and chemotherapy, but had failed and was intolerant to chemotherapy. Interventions: The patient had 5% tumor PD-L1 positivity with 22C3 pharmDx and received pembrolizumab (200 mg every 21 days) for 13 cycles. Outcomes: The disease remained well controlled according to the RECIST 1.1. criteria. He is currently under observation and waiting to start the next cycle of immunotherapy. Lesson: Our case report suggests that the use of anti-PD-1 therapy does show efficacy in the treatment of PPA and may provide a viable treatment option for patients.

Automated summary

Primary pleural angiosarcoma is a rare malignancy with poor prognosis, but anti-PD-1 therapy has shown efficacy as a viable treatment option for patients.